Achieve life sciences announces partnership with omnicom to execute integrated, data-driven launch of the first potential new treatment for nicotine dependence in nearly two decades

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need seattle and vancouver, british columbia, june 26, 2025 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it has named omnicom (nyse: omc) as its strategic innovation partner and agency of record to lead initiatives in support of achieve's planning for u.s. commercial launch. “we're excited to expand our partnership with omnicom, building on the strong foundation we've established over the past several years,” said jaime xinos, chief commercial officer of achieve life sciences.
OMC Ratings Summary
OMC Quant Ranking